WallStreetZenWallStreetZen

NASDAQ: SUPN
Supernus Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Supernus Pharmaceuticals revenue was $661.82M for the trailing 12 months ending Dec 31, 2024, with 6,600% growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $174.2M, down 0.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SUPN annual revenue was $661.8M, with 8.9% growth year-over-year.

SUPN past revenue growth

How has SUPN's revenue growth performed historically?

Company
8.94%
Industry
10.09%
Market
20.27%
SUPN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SUPN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SUPN's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SUPN revenue history

Current Revenue
$661.8M
Current Earnings
$73.9M
Current Profit Margin
11.2%

Be the first to know when SUPN announces revenue.

SUPN Revenue History By Year

SUPN Yearly RevenueSUPN RevenueSUPN ChangeSUPN Revenue Growth
2024-12-31$661.82M$54.30M+8.94%
2023-12-31$607.52M-$59.72M-8.95%
2022-12-31$667.24M$87.46M+15.09%
2021-12-31$579.78M$59.38M+11.41%
2020-12-31$520.40M$127.64M+32.50%
2019-12-31$392.76M-$16.14M-3.95%
2018-12-31$408.90M$106.66M+35.29%
2017-12-31$302.24M$87.24M+40.57%
2016-12-31$215.00M$67.54M+45.80%
2015-12-31$147.47M$54.79M+59.12%
2014-12-31$92.68M$80.66M+671.10%
2013-12-31$12.02M$10.54M+712.09%
2012-12-31$1.48M$677.00k+84.31%
2011-12-31$803.00k$697.00k+657.55%
2010-12-31$106.00k-$37.82M-99.72%
2009-12-31$37.93MN/AN/A

1 of 2

Supernus Pharmaceuticals Revenue FAQ

What was SUPN's revenue last quarter?

On Invalid Date, Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q4 2024 revenue of $174.16 million up 5.99% year over year. In the same quarter last year, Supernus Pharmaceuticals's revenue was $164.31 million.

What was Supernus Pharmaceuticals's revenue in 2024?

Supernus Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $661.82 million, a 8.94% increase year over year.

How much does Supernus Pharmaceuticals make in a day?

Based on Supernus Pharmaceuticals annual revenue for the past five years, SUPN makes an average of $1,663,971.51 per day.

What was Supernus Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, Supernus Pharmaceuticals's revenue has grown 8.94% year over year. This is 1.15 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.09%. Supernus Pharmaceuticals's revenue in the past year totaled $661.82 million.

How much does Supernus Pharmaceuticals make in a year?

Supernus Pharmaceuticals's revenue by year for the past five years is:
  • Supernus Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $661.82 million, a 8.94% increase year over year.
  • Supernus Pharmaceuticals's annual revenue for Dec 31, 2023 was $607.52 million, a 8.95% decrease from 2022.
  • Supernus Pharmaceuticals's annual revenue for 2022 was $667.24 million, a 15.09% increase from 2021.
  • Supernus Pharmaceuticals's annual revenue for 2021 was $579.78 million, a 11.41% increase from 2020.
  • Supernus Pharmaceuticals's annual revenue for 2020 was $520.40 million, a 32.5% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.